Pharmacokinetics and Clinical Evaluation of ¹²⁵ I-Radiolabeled Humanized CC49 Monoclonal Antibody (HuCC49ΔC _H 2) in Recurrent and Metastatic Colorectal Cancer Patients

Abstract

C(H)2 region deletion of HuCC49DeltaC(H)2 MAb did not alter the pharmacokinetics compared to murine CC49. The favorable partition coefficient K of HuCC49DeltaC(H)2 MAb into tumors supports its use in RIGS.